IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0772 -0,0012 (-0,11%) Petróleo Brent
82,73 -1,15 (-1,37%) Oro
2.366,90 +26,60 (+1,14%) Bitcoin EUR
56.417,56 -1.996,67 (-3,42%)
Longeveron Inc. (LGVN)
Después del cierre:
Longeveron Inc.
Life Science and Technology Park
1951 NW 7th Avenue Suite 520
Miami, FL 33136
United States
305 909 0840
https://longeveron.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 23
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer & Chairman | 74k | N/A | 1963 |
| Mr. Mohamed Wa'el Ahmed Hashad | CEO & Director | 781,56k | N/A | 1962 |
| Ms. Lisa A. Locklear M.B.A. | Executive VP & CFO | 248,38k | N/A | 1962 |
| Mr. Paul T. Lehr J.D. | International Executive Director, General Counsel & Secretary | 554,05k | N/A | 1968 |
| Dr. Dan Gincel Ph.D. | Senior Vice President of Strategic Collaborations & Scientific Affairs | N/A | N/A | 1971 |
| Dr. Nataliya Agafanova M.D. | Chief Medical Officer | N/A | N/A | 1970 |
| Ms. Elly Ryu | VP & Corporate Controller | N/A | N/A | 1982 |
Descripción
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Gobierno corporativo
El ISS Governance QualityScore de Longeveron Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
